From OCBC:
Goodpack Limited: Decent FY13 results
Goodpack’s FY13 results were in-line with
expectations. Revenue grew by a smaller 7.7% YoY to US$190.9m while PATMI
improved 13.4% YoY to US$51.3m as its cost saving initiatives helped to
offset higher depreciation and financing costs from a larger fleet and
increased borrowings respectively. Similar to last year (FY12), management
declared a final dividend of 2 S cents and a special dividend of 3 S cents.
Although we lower our revenue forecasts for FY14, we still expect growth
improvement following the commencement of key clients’ synthetic rubber
(SR) operations in Singapore and a new SR contract in Russia. In terms
of margins, we only expect a small drop-off as continued cost saving initiatives
should keep a lid on logistic and handling expenses. In light of its unchanged
fundamentals and recent share price correction, we maintain BUY on
Goodpack with a slightly lower fair value of S$1.69 (S$1.80 previously).
From Maybank KE:
Sino Grandness: Ready, Willing And Able; Buy, $1.05 - TP $1.89
SFGI SP | Mkt Cap USD240.2m | ADTV USD1.4m
Reiterate BUY and SGD1.89 TP. In light of the recent short seller’s
attack on China Minzhong, Sino Grandness’ management has been very
responsive and open in dealing with investors’ concerns and readily
agreed to hold a conference call with our clients yesterday despite the
extremely short notice given to them.
In all, the conference call was organised within 90 minutes and 20
clients participated. We think the information shared by management was
helpful and informative, and should go a long way to calming investor
concerns.
In our view, the share price drop in the past two days was purely
due to fallout from the Minzhong short selling incident. Fundamentals
are still firm and the biggest catalyst, the Garden Fresh IPO, still
lies ahead. We believe Sino looks more attractive today compared to
last week.
Wing Tai: Sturdy as a Tembusu Tree; Buy, $2.04 - TP $2.78
WINGT SP | Mkt Cap USD1.2b | ADTV USD1.2m
We reiterate our BUY recommendation on Wing Tai, with a slightly
higher TP of SGD2.78, pegged to a 30% discount to RNAV. A bumper
dividend of 12 cts/share has been proposed, translating to an
attractive FYJun13 yield of 5.9%.
Its FYJun13 core PATMI of SGD294m was in line with expectations.
Having achieved SGD885m worth of property sales in FY13, Wing Tai went
on to launch The Tembusu in mid-August. 220 units have been booked,
with an ASP of ~SGD1,500 psf.
The Group will remain selective in land acquisitions. Malaysia is
deemed its most attractive market in the near-term for new
investments, but the Group will continue to explore opportunities in
Singapore, HK and China.
From DBS:
FY13 results for Goodpack slightly above. The key variants
were the US$1.4m disposal gain of PPE and US$0.9m
forex gain in 4Q13. Goodpack is on track to achieve
volume growth of 250k boxes in FY14, underpinned by
the firm ramp up of new SR markets in Singapore and
Russia. It is also gaining traction in the autoparts market.
Maintain BUY with higher TP of S$2.00. The finalisation of
autopart contracts serve as an imminent catalyst.
2Q13 results for IHH Healthcare within expectations.
EBITDA margins improved with positive contribution
from new hospitals. Novena hospital turned in RM2m
EBITDA profit, on track for positive contribution in FY13.
Maintain HOLD, TP adjusted to S$1.50 (Prev S$ 1.55),
accounting for recent currency effects. While we believe
the long term prospects for healthcare remains positive
and IHH commands a premium due to its scarcity and
geographical spread, the stock is already trading at
43x/36x on FY13F/14F earnings.
Search for your stock recommendation here:
Thursday, August 29, 2013
Local Brokerages Stock Call 28 August 2013
Subscribe to:
Post Comments (Atom)
Disclaimers:
The Research Report is for your general and private
reading, and it is not a recommendation for any stock investment/trading.
There are Risk and Reward involved in stock investment/trading.
Readers should exercise caution and judgement when
making investment/trading decision from the report.
Past performance is never a good indication of Future performance.
Readers should seek the advice of professional, adviser
for any stock decision.
I will not be held responsible for any loss incurred from
stock decision from reading the research report.
Caveat Emptor!
reading, and it is not a recommendation for any stock investment/trading.
There are Risk and Reward involved in stock investment/trading.
Readers should exercise caution and judgement when
making investment/trading decision from the report.
Past performance is never a good indication of Future performance.
Readers should seek the advice of professional, adviser
for any stock decision.
I will not be held responsible for any loss incurred from
stock decision from reading the research report.
Caveat Emptor!
No comments:
Post a Comment